Enclomiphene Dosage Chart & Bloodwork Guide.

No, and it is important to know why. Repros Therapeutics developed it as Androxal, filed an NDA and received a Complete Response Letter in December 2015, in which the FDA stated the phase III study design was no longer adequate to demonstrate clinical benefit; the trials produced a testosterone number, not evidence that men felt or functioned better. The advisory committee meeting scheduled for November 2015 was cancelled and never held. The EMA refused marketing authorisation for the identical molecule (EnCyzix) in January 2018, citing both the missing symptom evidence and venous thromboembolism risk, and development was formally discontinued in April 2021. In the US it exists only as a compounded prescription product. It has never been added to the FDA’s 503A bulk drug substances list, which is what makes telehealth supply legally unsettled rather than routine, and it means there is no manufacturer label, no standardised strength, and no guaranteed potency behind whatever capsule you are handed.

Broadly yes, and the advantage is real but smaller than the marketing implies. In a 66-man retrospective where patients took both sequentially, enclomiphene raised testosterone a median 166 ng/dL versus 98 ng/dL for clomiphene, a difference that did not reach statistical significance (P=0.20). Where it clearly separated was tolerability: estradiol moved −5.92 pg/mL versus +17.50 pg/mL (P=0.001), with significantly less decreased libido (P=0.001), reduced energy (P=0.044) and mood change (P=0.03), and about five-fold lower odds of any documented adverse event (OR 0.18, 95% CI 0.07-0.44). Set against that, clomiphene is FDA-approved (in women), generic, cheap and pharmacy-standardised. Enclomiphene is none of those.

No. It does the opposite, and this is the single most robust finding in the whole evidence base. Over 16 weeks of phase III, enclomiphene held sperm concentration in the normal range with density up 11.7-15.2%, while the testosterone gel comparator cut sperm counts 32.8-56.6%. In the 6-month phase IIb study, 6 of 6 enclomiphene men had elevated counts (75-334 million/mL) against 2 of 5 on gel. The AUA testosterone deficiency guideline reflects this split directly: SERMs are a conditional option (Statement 27, Grade C) for men wanting to preserve fertility, while exogenous testosterone carries a strong Grade A recommendation against use in men currently trying to conceive.

There is no suppression to recover from, because you were never replacing testosterone; you were prompting your own pituitary. Trial subjects kept elevated testosterone for at least 7 days after the final capsule despite the ~10-hour half-life, then it drifts back toward wherever their own axis naturally sits. Being honest about the gap: no trial followed men long enough after discontinuation to say how fast or how completely that reversal happens, so anyone quoting you a precise figure is extrapolating. If the underlying driver was body fat, poor sleep or overtraining, that is what determines your landing point.

Both went through phase III and both work; the question is how much headroom you actually need. Convention is to start at 12.5 mg daily and titrate to 25 mg only if the 6-8 week morning panel leaves total testosterone short of roughly 400-450 ng/dL or symptoms have not shifted. Opening at 25 mg is not dangerous, but it destroys the information; you will never know whether you needed it, and estradiol effects plus side effects track dose. Going above 25 mg is off the map entirely: that is the top of the trial evidence, and steady-state levels stop climbing meaningfully past it.

The evidence is thin and you should treat it that way. Nearly every trial enrolled overweight or obese men aged 18-60 with confirmed secondary hypogonadism: two separate morning testosterone readings at or below 300 ng/dL, with LH still in a responsive range (1.4-9.4 mIU/mL in the 12-month study), BMI 30-42, waist ≥40 inches. That is a specific patient. The mechanism requires a pituitary that will respond and testes that can answer; both become less reliable with age, and no trial specifically tested men over 60. If your LH is already high, your problem is testicular and this drug cannot fix it.

Usually not, and adding one reflexively is a common self-inflicted injury. Enclomiphene already antagonises estrogen receptors at the pituitary, and in head-to-head data its net estradiol change was slightly negative rather than positive. Estradiol is not a waste product in men; it drives bone density, libido and lipid handling. Stacking an aromatase inhibitor on top of a SERM is one of the more reliable routes to flat libido, aching joints and low mood, which people then blame on the enclomiphene. If estradiol genuinely runs high on labs alongside symptoms, that is a dose conversation with a prescriber, not a second drug you add blind.

Baseline: two separate early-morning total testosterone draws (the AUA requires two before diagnosing deficiency), plus free testosterone, LH and FSH (those two are what distinguish secondary from primary hypogonadism and determine whether the drug can work at all), estradiol, SHBG, prolactin, a CBC for hematocrit, LFTs, a lipid panel, and PSA if you are over 40. Recheck at 6-8 weeks to make the titration call, then every 6-12 months per guideline. Watch hematocrit even though you are not taking exogenous testosterone: the trials excluded men above 54% and that remains the practical line.